Clinical utility of HCV core antigen detection and quantification using serum samples and dried blood spots in people who inject drugs in Dar-es-Salaam, Tanzania

Journal of the International AIDS Society

Volumn 20, Issue 1, 2017, Pages

  Mohamed, Zameer ^a   Mbwambo, Jessie ^b   Shimakawa, Yusuke ^c   Poiteau, Lila ^d   Chevaliez, Stéphane ^d   Pawlotsky, Jean Michel ^d   Rwegasha, John ^e   Bhagani, Sanjay ^f   Taylor Robinson, Simon D ^a   Makani, Julie ^b   Thursz, Mark R ^a   Lemoine, Maud ^a  

^a ST MARY S HOSPITAL   (United Kingdom)

^b MUHIMBILI UNIVERSITY OF HEALTH AND ALLIED SCIENCES   (Tanzania)

^c INSTITUT PASTEUR   (France)

^d HENRI MONDOR HOSPITAL   (France)

^e MUHIMBILI NATIONAL HOSPITAL   (Tanzania)

^f ROYAL FREE HOSPITAL   (United Kingdom)

Author keywords

Africa; dried blood spot; HCV core antigen; hepatitis C virus (HCV); people who inject drugs; screening

Indexed keywords

ALANINE AMINOTRANSFERASE; ANTIRETROVIRUS AGENT; ASPARTATE AMINOTRANSFERASE; GAMMA GLUTAMYLTRANSFERASE; HEPATITIS C ANTIGEN; HEPATITIS C CORE ANTIGEN; UNCLASSIFIED DRUG; VIRUS RNA; CORE PROTEIN;

ADULT; ANTIGEN DETECTION; ANTIRETROVIRAL THERAPY; ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DRIED BLOOD SPOT TESTING; DRUG ADMINISTRATION; FEMALE; GENOTYPE; HEPATITIS B; HEPATITIS C; HEPATITIS C VIRUS GENOTYPE 1; HEPATITIS C VIRUS GENOTYPE 4; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; NUCLEIC ACID ANALYSIS; OPIATE SUBSTITUTION TREATMENT; PHYLOGENY; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; TANZANIA; VIREMIA; VIRUS LOAD; BLOOD; GENETICS; HEPACIVIRUS; ISOLATION AND PURIFICATION; METABOLISM; PHYSIOLOGY; PROCEDURES; VIROLOGY;

ADULT; DRIED BLOOD SPOT TESTING; FEMALE; GENOTYPE; HEPACIVIRUS; HEPATITIS C; HEPATITIS C ANTIGENS; HUMANS; MALE; PHYLOGENY; RNA, VIRAL; SENSITIVITY AND SPECIFICITY; TANZANIA; VIRAL CORE PROTEINS; VIRAL LOAD;

EID: 85040601178     PISSN: None     EISSN: 17582652     Source Type: Journal    
DOI: 10.7448/IAS.20.1.21856     Document Type: Article

References (28)

1. Mohd Hanafiah K, Groeger J, Flaxman AD, Wiersma ST., Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence. Hepatology. 2013; 57 (4): 1333-42.
2. Mortality GBD, C. Causes of death. Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet. 2015; 385 (9963): 117-71.
3. Gower E, Estes C, Blach S, Razavi-Shearer K, Razavi H., Global epidemiology and genotype distribution of the hepatitis C virus infection. J Hepatol. 2014; 61 (1 Suppl): S45-57.
4. WHO. Towards the elimination of hepatitis B and C by 2030. 2016 [cited 2016 Nov 23]. Available from: http://www.worldhepatitissummit.org/docs/default-source/default-document-library/2015/resources/towards-elimination-dr-gottfried-hirnschall.pdf?sfvrsn-6
5. WHO. Guidelines on Heaptitis B and C Testing 2017. Available from: http://apps.who.int/iris/bitstream/10665/254621/1/9789241549981-eng.pdf?ua-1
6. WHO. Draft global health sector strategy on viral hepatitis, 2016-2021. 2016. Available from: http://www.who.int/hepatitis/strategy2016-2021/Draft-global-health-sector
7. Lemoine M, Thursz M., Viral hepatitis: scaling up HCV treatment in resource-limited countries. Nat Rev Gastroenterol Hepatol. 2015; 12 (4): 193-94.
8. Chevaliez S, Soulier A, Poiteau L, Bouvier-Alias M, Pawlotsky J-M., Clinical utility of hepatitis C virus core antigen quantification in patients with chronic hepatitis C. J Clin Virol. 2014; 61 (1): 145-48.
9. Ticehurst JR, Hamzeh FM, Thomas DL., Factors affecting serum concentrations of hepatitis C virus (HCV) RNA in HCV genotype 1-infected patients with chronic hepatitis. J Clin Microbiol. 2007; 45 (8): 2426-33.
10. Morrill JA, Shrestha M, Grant RW., Barriers to the treatment of hepatitis C. Patient, provider, and system factors. J Gen Intern Med. 2005; 20 (8): 754-58.
11. Coats JT, Dillon JF., The effect of introducing point-of-care or dried blood spot analysis on the uptake of hepatitis C virus testing in high-risk populations: a systematic review of the literature. Int J Drug Policy. 2015; 26 (11): 1050-55.
12. UNODC. World drug report 2015. https://www.unodc.org/documents/wdr2015/World-Drug-Report-2015.pdf
13. Bowring AL, Luhmann N, Pont S, Debaulieu C, Derozier S, Asouab F, et al., An urgent need to scale-up injecting drug harm reduction services in Tanzania: prevalence of blood-borne viruses among drug users in Temeke District, Dar-es-Salaam, 2011. Int J Drug Policy. 2013; 24 (1): 78-81.
14. Muasya T, Lore W, Yano K, Yatsuhashi H, Owiti FR, Fukuda M, et al., Prevalence of hepatitis C virus and its genotypes among a cohort of drug users in Kenya. East Afr Med J. 2008; 85 (7): 318-25.
15. Duchesne L, Njouom R, Lissock F, Tamko-Mella GF, Rallier S, Poiteau L, et al., HCV Ag quantification as a one-step procedure in diagnosing chronic hepatitis C infection in Cameroon: the ANRS 12336 study. J Int AIDS Soc. 2017; 20 (1): 1-8.
16. Bronowicki J-P, Ouzan D, Asselah T, Desmorat H, Zarski J-P, Foucher J, et al., Effect of ribavirin in genotype 1 patients with hepatitis C responding to pegylated interferon alfa-2a plus ribavirin. Gastroenterology. 2006; 131 (4): 1040-48.
17. Lepretre A, Ba I, Lacombe K, Maynart M, Toufik A, Ndiaye O, et al., Prevalence and behavioural risks for HIV and HCV infections in a population of drug users of Dakar, Senegal: the ANRS 12243 UDSEN study. J Int AIDS Soc. 2015; 18: 19888.
18. Al -O-OME. Seroprevalence of HIV, HBC and HCV in injecting drug users in Nairobi, Kenya: World Health Organization drug injecting study Phase II findings. 15th International AIDS Conference; 2004; Bangkok.
19. Rao VB, Johari N, Du Cros P, Messina J, Ford N, Cooke GS., Hepatitis C seroprevalence and HIV co-infection in sub-Saharan Africa: a systematic review and meta-analysis. Lancet Infect Dis. 2015; 15 (7): 819-24.
20. Freiman JM, Tran TM, Schumacher SG, White LF, Ongarello S, Cohn J, et al., Hepatitis C core antigen testing for diagnosis of hepatitis C virus infection: a systematic review and meta-analysis. Ann Intern Med. 2016; 165 (5): 345-55.
21. Soulier A, Poiteau L, Rosa I, Hézode C, Roudot-Thoraval F, Pawlotsky J-M, et al., Dried blood spots: a tool to ensure broad access to hepatitis C screening, diagnosis, and treatment monitoring. J Infect Dis. 2016; 213 (7): 1087-95.
22. Van Tilborg M, Cherepanov GHV, Aquino A, Mazulli T, Kowgier M, Janssen HL, et al., Can dried blood spots be used for diagnosis of chronic hepatitis C infection, even when they are stored under non-ideal conditions? In: EASL. 2017.
23. Roberts T, Simplified HCV diagnostics. In: INHSU. 2016.
24. Thursz M, Lacombe K., Breaking down barriers to care in hepatitis C virus infection. J Infect Dis. 2016; 213 (7): 1055-56.
25. WHO. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection. 2013. Available from: http://apps.who.int/iris/bitstream/10665/85321/1/9789241505727-eng.pdf?ua-1
26. Kania D, Bekalé AM, Nagot N, Mondain A-M, Ottomani L, Meda N, et al., Combining rapid diagnostic tests and dried blood spot assays for point-of-care testing of human immunodeficiency virus, hepatitis B and hepatitis C infections in Burkina Faso, West Africa. Clin Microbiol Infect. 2013; 19 (12): E533-41.
27. Chevaliez S, Feld J, Cheng K, Wedemeyer H, Sarrazin C, Maasoumy B, et al., Clinical utility of HCV core antigen detection and quantification in the diagnosis and management of patients with chronic hepatitis C receiving an all-oral, interferon-free regimen. Antivir Ther. 2016. Available from: https://www.ncbi.nlm.nih.gov/labs/articles/27115431/
28. Mederacke I, Wedemeyer H, Ciesek S, Steinmann E, Raupach R, Wursthorn K, et al., Performance and clinical utility of a novel fully automated quantitative HCV-core antigen assay. J Clin Virol. 2009; 46 (3): 210-15.